

How to approach pancreatic cancer after neoadjuvant treatment: assessment of resectability using multidetector CT and tumor marker

European Radiology

32, 56-66

DOI: [10.1007/s00330-021-08108-0](https://doi.org/10.1007/s00330-021-08108-0)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: Role of the Radiologist and Oncologist in the Era of Precision Medicine. <i>Diagnostics</i> , 2021, 11, 2166.	1.3	7
2	Imaging Assessment of Pancreatic Cancer Resectability After Neoadjuvant Therapy: <i>AJR</i> Expert Panel Narrative Review. <i>American Journal of Roentgenology</i> , 2022, 218, 570-581.	1.0	11
4	Glycoconjugate Nanoparticle-Based Systems in Cancer Immunotherapy: Novel Designs and Recent Updates. <i>Frontiers in Immunology</i> , 2022, 13, 852147.	2.2	4
5	Plasma thioredoxin reductase: a potential diagnostic biomarker for gastric cancer. <i>Carcinogenesis</i> , 2022, 43, 736-745.	1.3	8
6	Prognostic value of major pathological response following neoadjuvant therapy for non resectable pancreatic ductal adenocarcinoma. <i>Pancreatology</i> , 2023, 23, 266-274.	0.5	0
7	High-resolution pancreatic computed tomography for assessing pancreatic ductal adenocarcinoma resectability: a multicenter prospective study. <i>European Radiology</i> , 0, , .	2.3	0